The Diagnostic Value of Serum Oncostatin M and Galactin 3 as Biomarkers in Diagnosis of Ulcerative Colitis Disease
Not applicable · Testing ELISA test · Sites not listed yet · Sohag University
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
This study is testing ELISA test (a diagnostic test) as a way to diagnose or measure disease. Condition(s) listed: Ulcerative Colitis Disease Patients and Normal Patients.
Participants are assigned to groups by chance (randomized).
It is blinded: participants and the study team do not know who receives what.
This study does not use drug-development phases (it may test a device, diet, procedure, app, or care approach).
Who can join
- Ages 18 to 55
- Any sex
- Healthy volunteers accepted
Some of the main requirements, copied from the record:
- Patients, both male and female, who are over the age of 18 and were identified as having ulcerative colitis based on histological, clinical, and endoscopic criteria.
- Group I The study group will include 40 normal healthy subject. Group II The study group will include 50 patients newly diagnosed with confirmed ulcerative colitis who divided into active and non active.
- Ulcerative colitis activity diagnosed by Simple Clinical Colitis Activity Index (SCCAI) is a diagnostic tool and questionnaire used to assess the severity of symptoms in people who suffer from ulcerative colitis(Walmsley et al.,1998). The…
Plus 1 more requirement(s). There are also 1 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 90 participants are expected to take part.
- Start date: 2025-05-15 (planned).
- Main results expected around 2026-05 (estimate from the record).
- No study sites are listed yet. Check the official record for contact details.
Main thing being measured
- Assessment of Serum value of oncosatin M and galactin 3 patients with ulcerative colitis (1year)
In the researchers’ words
Inflammatory bowel diseases (IBD)-Crohn's disease (CD), ulcerative colitis (UC) and inflammatory bowel disease unclassified (IBD-U)-are chronic inflammatory conditions that mainly affect the gastrointestinal tract but might also involve other organs, so they are considered systemic diseases. IBD is mainly diagnosed in young people, and is associated with significant morbidity and disability (Kaplan, 2015).
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Not yet recruiting |
|---|---|
| Phase | Not applicable |
| Study type | Interventional |
| Conditions | Ulcerative Colitis Disease Patients and Normal Patients |
| Lead sponsor | Sohag University |
| Enrollment | 90 (estimated) |
| Start date | 2025-05-15 |
| Primary completion (est.) | 2026-05 |
| First posted | 2025-05-06 |
| Last updated | 2025-05-06 |
| Official title | The Diagnostic Value of Serum Oncostatin M and Galactin 3 as Biomarkers in Diagnosis of Ulcerative Colitis Disease |
| ClinicalTrials.gov ID | NCT06959654 |
Interventions
- ELISA test (Diagnostic Test)
ELISA test to evaulate serum oncostatin M and galactin 3 in two group of patientsL
Full eligibility criteria (from the record)
Inclusion Criteria: * Patients, both male and female, who are over the age of 18 and were identified as having ulcerative colitis based on histological, clinical, and endoscopic criteria. Group I The study group will include 40 normal healthy subject. Group II The study group will include 50 patients newly diagnosed with confirmed ulcerative colitis who divided into active and non active. Ulcerative colitis activity diagnosed by Simple Clinical Colitis Activity Index (SCCAI) is a diagnostic tool and questionnaire used to assess the severity of symptoms in people who suffer from ulcerative colitis(Walmsley et al.,1998). The calculated score ranges from 0 to20, where active disease is a score of 5 or higher. The score is determined by asking the person with colitis questions regarding: Bowel frequency at day/night Urgency of defecation Blood in stool General health Extracolonic manifestations Exclusion Criteria: * Those with concomitant systemic inflammation as Rheumatoid arthritis(RA) and Bronchial asthma (BA), those with a history of malignancy, Also, patients who were discovered to have autoimmune disease or microscopic colitis and Crohn's disease, ulcerative colitis patients who are on treatment.
Locations (0)
No sites listed yet. The official record has contact information.
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.